Please assess the completion status of the following clinical trial:

Trial Title: 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Hodgkin's lymphoma or, using the World Health Organization (WHO) classification, aggressive non-Hodgkin's lymphoma including:~  * Large B- or T-cell lymphomas (including transformed lymphomas)~ * Mantle cell lymphoma~ * Immunoblastic lymphoma~* At least 1 unidimensionally measurable lesion~  * At least 2 centimeter (cm) by conventional techniques OR~ * At least 1 cm by spiral computerized tomography (CT) scan~ * Lymph nodes no greater than 1 cm in the short axis are considered normal~* Relapsed or refractory disease after first-line chemotherapy~* Cohort 1:~  * No more than 3 prior conventional cytotoxic chemotherapy regimens~ * Must have had at least a partial response (PR) lasting no more than 6 months or refractory disease~ * Patients with disease refractory to or relapsed less than 100 days from peripheral blood stem cell (PBSC) transplantation are not eligible~* Cohort 2:~  * No limit on prior treatment~ * Must have had at least a PR to the last therapy lasting at least 6 months~ * Patients who have received high-dose chemotherapy as part of peripheral blood stem cells (PBSC) transplantation are eligible if relapse occurred at least 100 days after transplantation~* No clinically significant pleural effusions or ascites~* No active brain or leptomeningeal metastases~  * Treated Central nervous system (CNS) disease allowed~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 75,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin less than 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase/alanine aminotransferase (AST/ALT) no greater than 2.5 times ULN (4 times ULN if liver involvement)~* Alkaline phosphatase no greater than 5 times ULN~Renal~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 50 mL/min~Cardiovascular~* No symptomatic congestive heart failure~* No New York Heart Association class III or IV heart disease~* No unstable angina pectoris~* No cardiac arrhythmia~* No myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months~* No history of orthostatic hypotension~* No ECG evidence of acute ischemia or significant conduction abnormality (e.g., bifascicular block or 2nd or 3rd degree atrioventricular blocks)~* No uncontrolled hypertension requiring active manipulation of antihypertensive medications~* No grade III or IV edema~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No ongoing or active infection~  * Febrile episodes up to 38.5° Celsius without signs of active infection allowed~* No other concurrent active cancer~* No other concurrent serious medical illness~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* At least 3 months since prior monoclonal antibody therapy (e.g., rituximab)~Chemotherapy~* See Disease Characterisitics~* At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered~Endocrine therapy~* At least 7 days since prior steroids~* No concurrent steroids~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy and recovered~Surgery~* More than 4 weeks since prior major surgery~Other~* No prior antifolates~* No concurrent folic acid supplementation~* No other concurrent investigational agents~* No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients~* No other concurrent investigational or commercial agents or therapies with the intent to treat the malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 135 mg/m^2 Pralatrexate 1/2 weeks (Type: EXPERIMENTAL): Pralatrexate (PDX) 135 mg/m\^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.
- 30 mg/m^2 Pralatrexate 3/4 weeks (Type: EXPERIMENTAL): PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.
- 30 mg/m^2 Pralatrexate 6/7 weeks (Type: EXPERIMENTAL): PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
- 45 mg/m^2 Pralatrexate 6/7 weeks (Type: EXPERIMENTAL): PDX 45 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
- 270 mg/m^2 Pralatrexate 2/4 weeks (Type: EXPERIMENTAL): PDX (270 mg/m\^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).